Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Document › Details

Biognosys AG. (8/8/19). "Press Release: Biognosys Completes Series G Financing Round to Accelerate its Expansion into Clinical Trials Market". Schlieren.

Organisations Organisation Biognosys AG
  Organisation 2 NN (NO NAME)
  Group OTHER
Products Product mass spectrometry-based proteomic research test
  Product 2 venture capital
Index term Index term Biognosys–SEVERAL: investment, financing round Series G from existing + new institutional + private investors
Persons Person Rinner, Oliver (Biognosys 201212– CSO + founder before CEO)
  Person 2 Novak, Lidia (Biognosys 2019089 CFO)
     


Biognosys closes Series G round with new and existing investors to accelerate implementation of discovery proteomics in clinical trials.


Biognosys, a Swiss proteomics company, continues realizing its ambition to enable clinical researchers to directly measure and quantify thousands of proteins from patient tissues in clinical trials by offering its next-generation label-free proteomics technology. To accelerate this development, the company has raised new funds in Series G financing round.

Biognosys provides proteomics research services to innovative pharma and biotech firms. They use the company’s technology in their pre-clinical research, providing deep and precise protein expression profiling for the development of biomarkers and analysis of mode of action. As demand for the use of these services in the clinical phase is growing, the new financing round will help the company to further scale up its operations and start serving clients’ drug development projects in the clinical phases.

Dr. Oliver Rinner, Founder and CEO of Biognosys, says: “We are striving to provide the deepest and most precise proteomics data to our clients. We are very excited with the perspective to be pioneers in bringing discovery proteomics to clinical trials and provide our advanced data analysis services at a much larger scale.”

The financing round includes a new industrial investor, in addition to existing institutional and private shareholders. The funds will be invested into building a new GCP-certified facility in Switzerland, increasing current operational capacity as well as enhancing the company’s sales force, further expanding its commercial presence in the US (both East and West Coast), Europe, and Asia.


Media Contact:

Lidia Novak, CFA
Chief Financial Officer
Mobile +41 (0) 79 710 74 15
lidia.novak@biognosys.com


About Biognosys:

Biognosys is a leader in next-generation proteomics, dedicated to transforming life science research by making the most advanced proteomics tools available to researchers. The company offers a suite of products and services to decode the proteome and equip researchers from all fields with a deep view of protein expression in cells, tissues, or body fluids. Biognosys’ technology is based on high-resolution mass spectrometry, combined with a novel parallel signal processing approach, for unprecedented quantification of large proteomes in a single experiment. More information at: www.biognosys.com

   
Record changed: 2019-12-03

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Biognosys AG


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top